Administration of the off-label targeted therapy in accordance to the comprehensive genomic profiling
What is this about?
Comprehensive genomic profiling contributes to the development of precision medicine, but more specifically oncology. The CGP analysis reports mutations with opted targeted therapy. On-label (for the patients tumor type) therapy is available and easy accessible. However, off-label targeted therapy is not approved.
Why is this important?
Off-label therapy may improve patients outcomes. Also, it is important to develop standardized operative procedure in choosing the appropriate treatment in accordance to the CGP.
For whom is this important?
What are the best practices?
It is important to develop standardized operative procedures, tumor mutational board and establish protocol when choosing and administering the targeted therapy in accordance to the CGP.
Dora Cerina contributed to this theme. Latest contribution was Feb 22, 2021